Mast Cells as Targets for the Therapy of Inflammatory Bowel Disease
The etiology and pathogenesis of inflammatory bowel disease (IBD) is poorly understood. However, numerous studies have demonstrated that immunological and inflammatory responses are activated during this disease. A better understanding of these events will help identify appropriate therapeutic inter...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1990-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1990/619243 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The etiology and pathogenesis of inflammatory bowel disease
(IBD) is poorly understood. However, numerous studies have demonstrated that
immunological and inflammatory responses are activated during this disease. A
better understanding of these events will help identify appropriate therapeutic
interventions. Mast cell hyperplasia is a prominent feature of inflamed intestinal
tissue in IBD. Intestinal mast cells are heterogeneous and at least two populations
are present in the human intestine. The authors' objective is to explore mast cell
properties, activation and mediators that are involved in the induction, maintenance
and perpetuation of inflammatory lesions in the intestine. Although
some therapies used in IBD can modulate mast cell activities, whether these
actions are important in the beneficial effects of the drugs is unknown. Future
drug development targeted to the inhibition of mast cells might be of therapeutic
value. However, a cascade of different cellular events are involved in IBD
development. The complexity of the disease raises difficulties in the development
of therapies. Multiple drugs, selective for different phases of the disease or acting
on different cells, might be most appropriate, rather than a single, all-encompassing
therapeutic agent. |
|---|---|
| ISSN: | 0835-7900 |